



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Boceprevir (Standard)

Cat. No.:	HY-10237R
CAS No.:	394730-60-0
Molecular Formula:	C ₂₇ H ₄₅ N ₅ O ₅
Molecular Weight:	519.68
Target:	SARS-CoV; HCV Protease; HCV
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K _i of 14 nM in both enzyme assay and an EC ₉₀ of 350 nM in cell-based replicon assay ^{[1][2][3][4][5]} . Boceprevir inhibits SARS-CoV-2 3CL ^{pro} activity ^[6] .
IC₅₀ & Target	Ki: 14 nM (HCV NS3 protease) ^[1]

REFERENCES

- [1]. Njoroge FG, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. *Acc Chem Res.* 2008 Jan;41(1):50-9.
- [2]. Yao M, et al. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity. *PLoS One.* 2016 Mar 4;11(3):e0150894.
- [3]. Coilly A, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. *Antimicrob Agents Chemother.* 2012 Nov;56(11):5728-34.
- [4]. Berenguer M, et al. New developments in the management of hepatitis C virus infection: focus on boceprevir. *Biologics.* 2012;6:249-56.
- [5]. Burton MJ, et al. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers. *South Med J.* 2012 Aug;105(8):431-6.
- [6]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. *Signal Transduct Target Ther.* 2021 May 29;6(1):212.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA